IQ4I Research & Consultancy Published a New Report on “Active Pharmaceutical Ingredients Global Market": Estimated to be Worth $173.5 Billion by 2020

San Francisco, CA, January 27, 2015 --(PR.com)-- IQ4I Research & Consultancy published a new report on “Active Pharmaceutical Ingredients Global Market – Forecast To 2020” which analyzes and studies the major market drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and Rest of the World

IQ4I’s Report Contains 112 market data tables and 30 figures spread through 282 pages and an exhaustive TOC on “Active Pharmaceutical Ingredients Global Market [Synthesis (Synthetic chemical API, Biotech API and HPAPI), Customer Base (Synthetic chemical API, Biotech API and HPAPI), Business Type (Captive and Merchant) and Therapeutic Application (Anti-infectives, Oncology, Cardiovascular and hematopoietic system, CNS, Respiratory, Gastrointestinal, Hormonal-related and Metabolic disorders, Genitourinary disorders, Musculo-skeletal diosorders and Others), Region (North America, Europe, Asia-Pacific and Rest of the World)]

The global Active Pharmaceutical Ingredients market is expected to reach $173.5 billion by 2020. This report analyzes the API market in terms of market revenue ($ Billion) for all segments, analysis is performed by synthesis type (Synthetic Chemicals API, Biotech API, HPAPI), Business type (Captive and Merchant) and therapeutic applications.

The API market is mainly driven by factors such as patent expiration of major drugs that increased generic drug sales, government initiatives, increasing aged population and regional penetration, local manufacturer expansion and high uptake of biologics. However, financial crisis, stringent regulatory policies, less investment in pharmaceutical industry and fragmented market are the factors restraining the market growth. To improve efficiency and productivity, the global API manufacturers depend on outsourcing by reducing internal capability in R&D, production and marketing drugs in order to avoid risk. Hence demand for CRO/CMOs is increased especially for small molecule drugs, generic drugs and biologic drugs in the market.

In 2013, the North America accounted for the largest share of 38% in 2013. Asia-Pacific (APAC) region is expected to grow at the highest CAGR from 2014 to 2020. Patent expiry and low operation costs are driving the Asia-Pacific API market, but high competition and government policies are hampering the market. Synthetic API holds a major share, but the Biotech APIs are booming segment in this region. The key players in the Asia-Pacific region are Dr. Reddy’s Laboratories, Lupin Pharma, Ranbaxy Laboratories, Sun Pharma, Zhejiang Hisun Pharmaceutical Co, Zhejiang Huahai Pharmaceuticals Co, Astellas pharma Inc., Daiichi Sankyo Ltd., Celltrion and Samsung Bioepis.

Teva pharmaceuticals (Israel) is the largest player in the API market with a share of percentage, followed by Lupin (India) and Sun Pharma (India) accounting percentage and shares respectively in 2013. The API market is consolidated, with major players accounting for more than 80% market share in 2013. Top ten major players include Teva Active Pharmaceutical Industries Limited (Israel), Ranbaxy Laboratories (India), Dr. Reddy's Lab (India), Boehringer Ingelheim GmbH (Germany), Lonza group (Switzerland), Lupin (India), Novartis (Switzerland), Aurobindo pharma (India), and Albemarle Corporation (U.S.).

Reasons for buying this report:

· Market assessment of all segments and sub segments of API market
· In-depth market sizing analysis of various segments such as synthetic chemicals API, biotech API, HPAPI, Captive and Merchant APIs and more than 11 API therapeutic applications market
· Regulatory scenario across the globe
· Major player profiles and their competitive landscaping